IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women
This study has been completed.
Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00594373
First received: January 2, 2008
Last updated: September 23, 2013
Last verified: September 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Topical microbicides, substances that kill microbes, are being studied to prevent sexual transmission of HIV and other disease-causing agents. In the future, topical microbicides may be applied vaginally to prevent both acquisition and transmission of HIV and other sexually transmitted infections (STIs). The purpose of this study is to assess whether there is a measurable response to daily applications of a topical microbicide, 1% tenofovir gel, in women at low risk for HIV infection.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: Tenofovir gel Drug: Tenofovir gel placebo | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Prevention |
| Official Title: | Effect of Repeated Applications of Tenofovir Gel on Mucosal Mediators of Immunity and Intrinsic Antimicrobial Activity of Cervicovaginal Secretions in Women at Low Risk for HIV-1 Infection |
Resource links provided by NLM:
Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):
Primary Outcome Measures:
- Changes in cytokines, chemokines, and other mediators of innate immunity through examination of cervicovaginal secretions [ Time Frame: At Days 3, 7, 14, and 21 ]
Secondary Outcome Measures:
- Changes in antimicrobial activity of cervicovaginal secretions [ Time Frame: At Day 14 ]
| Enrollment: | 30 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Application of 1% tenofovir gel for 14 consecutive days between menses
|
Drug: Tenofovir gel
1 gm/100 ml of 1% tenofovir gel vaginally daily
Other Names:
|
|
Placebo Comparator: 2
Application of 1% tenofovir placebo gel for 14 consecutive days between menses
|
Drug: Tenofovir gel placebo
1 gm/100 ml of placebo gel vaginally daily
|
Detailed Description:
A new approach to HIV prevention currently being studied is the use of topical microbicides. This study will measure the mucosal response to daily intravaginal applications of 1% tenofovir gel versus placebo in two groups of women at low risk for HIV infection.
The duration of this study for each participant is 21 days. Study participants will be randomly assigned to one of two study groups. Group 1 participants will apply 1% tenofovir gel daily for 14 consecutive days between menses. Group 2 participants will apply placebo gel for 14 consecutive days between menses.
Study visits will occur on Days 3, 7, 14, and 21. Study entry will occur 2 to 6 days following the menses and within 30 days of screening. Medical and sexual history, a pelvic exam, cervicovaginal lavage sample collection, blood collection, vaginal pH testing, STI testing, and adverse effect reporting will occur at all visits. All participants will be asked to complete a diary throughout the study; this diary will be reviewed at all study visits. A Pap smear will be obtained at screening if documentation of a negative Pap smear result within the last year is not available.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Normal menstrual history with regular cycles and with a minimum of 21 days between menses
- Sexually abstinent or in a stable, mutually monogamous relationship with a partner who is HIV uninfected
- Agree to abstain from sexual intercourse and to not use vaginal products within 48 hours of study entry and for the duration of the study
Exclusion Criteria:
- HIV infected
- Sexually transmitted infection within 6 months of study entry
- Use of nontherapeutic intravenous drugs within 12 months of study entry
- Menopausal
- Currently using hormonal contraception or have used hormonal contraception within 2 months of study entry
- Menstruating at screening or enrollment visits
- Positive urine culture
- Positive chlamydia, gonorrhea, or trichomonas result at screening
- Abnormal Pap smear
- Clinically detectable genital abnormality. More information on this criterion can be found in the protocol.
- History of toxic shock syndrome or a history of symptoms suggesting toxic shock syndrome
- History of intermenstrual bleeding within 3 months of study entry
- Previous gynecologic surgery or have received treatment for syphilis, genital herpes, chlamydia, gonorrhea, trichomonas, or genital warts within 6 months of study entry
- Received treatment for Candida, bacterial vaginosis, or urinary tract infection within 1 month of study entry
- Have douched or used vaginal products, including lubricants, feminine hygiene products, vaginal drying agents, and sex toys within 48 hours of study entry
- Acute or chronic hepatitis B virus infection
- Liver or kidney abnormalities
- Oral antibiotics within 7 days of study entry
- Pregnant, less than 6 months postpartum, or breastfeeding
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00594373
Please refer to this study by its ClinicalTrials.gov identifier: NCT00594373
Locations
| United States, New York | |
| Albert Einstein College of Medicine - East Campus GCRC (Herold) Non-Network CRS | |
| Bronx, New York, United States, 10461 | |
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
| Principal Investigator: | Marla Keller, MD | Albert Einstein College of Medicine, Inc. |
| Principal Investigator: | Betsy Herold, MD | Albert Einstein College of Medicine, Inc. |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00594373 History of Changes |
| Other Study ID Numbers: |
TFV 010 10443 ( Registry Identifier: DAIDS ES ) U01AI069551 ( US NIH Grant/Contract Award Number ) |
| Study First Received: | January 2, 2008 |
| Last Updated: | September 23, 2013 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Microbicide HIV Seronegativity |
Additional relevant MeSH terms:
|
Infection HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Tenofovir Anti-Infective Agents Antiviral Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents |
ClinicalTrials.gov processed this record on June 28, 2017